“We left the call encouraged that Riata is performing well ... better than many had thought ... and that [St. Jude’s] share could benefit from the recent safety concerns.”

— Rick Wise, Bear Stearns med-tech analyst writing in a research note after a conference call his firm hosted that he has more confidence that St. Jude Medical’s (St. Paul, Minnesota) Riata 7 Fr ICD lead may dodge the recall bullet that felled Medtronic’s 6.6 Fr Sprint Fidelis defibrillation leads earlier this month, “Contrary to rumor, St. Jude says, Riata not next ICD lead recalled,” pp. 1,7.